New Somatostatin-derived substances for the treatment of neuropathic pain and related disorders
Neuropathic pain is rather resistant
to conventional analgesics. Therefore, different approaches must be taken to treat neuropathic pain. One possibility is the use of agents acting at the level of the sensory nerve terminals themselves to inhibit the release of these pro-inflammatory/pronociceptive sensory neuropeptides. Such agents may form the basis for the development of a new group of anti-inflammatory and analgesic drugs. In this invention Somatostatin-derived substances were developed that can inhibit inflammation without accompanying endocrine side effects. Furthermore they exhibit satisfactory half life and bioavailability, especially after oral administration.
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Novel genetic plant regeneration approach
…without the application of phytohormones. Researchers develop a novel plant regeneration approach by modulating the expression of genes that control plant cell differentiation. For ages now, plants have been the…
Roadmap to close the carbon cycle
A holistic approach to reach net-zero carbon emissions across the economy. A major approach to achieving net-zero carbon emissions relies on converting various parts of the economy, such as personal…
Cost-effective, high-capacity, and cyclable lithium-ion battery cathodes
Charge-recharge cycling of lithium-superrich iron oxide, a cost-effective and high-capacity cathode for new-generation lithium-ion batteries, can be greatly improved by doping with readily available mineral elements. The energy capacity and…
